Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.
Barr PM, et al. Among authors: jaeger u.
Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.
Blood. 2017.
PMID: 28373262
Free PMC article.
Clinical Trial.